No abstract available.
Diagnosis* ; Prostate* ; Prostatic Neoplasms* ; Ultrasonography*

No abstract available.
Lithotripsy* ; Shock* ; Ureter* ; Ureteroscopy*

No abstract available.

No abstract available.
Hernia*

Patients with advanced urothelial tumors that relapse or persist following conventional therapy have poor prognosis. Management of the patients with recurrent local or disseminated urothelial tumors presents a difficult clinical problems. In 1985 Sternberg et al reported 71% of significant tumor regression and 50% of complete clinical remission with M-VAC (methotrexate, vinblastine, doxorubicin and Cisplatin) combination chemotherapy for treatment of advanced urothelial transitional cell carcinomas. Herein, we have experienced 13 cases of M-VAC combination chemotherapy in advanced urothelial tumors. Complete and partial remission was in achieved 46.2 per cent of the patients clinically, while 15.4 percent had a minor response and 38.4 per cent had progression with median survivals of 11.5, 8.5 and 7.4 months. Toxicity was significant. 15.4 per cent of the patients having experienced nadir sepsis, 30.8 per cent mucositis and 7.6 per cent cardiac toxicity. Median cycle length varied from 31.6 to 41.7 days for the first and 5th cycle respectively. This regimen has been efficacious in selected patients with advanced urothelial tumors.
Carcinoma, Transitional Cell ; Doxorubicin* ; Drug Therapy, Combination ; Humans ; Mucositis ; Prognosis ; Recurrence ; Sepsis ; Vinblastine*

No abstract available.
Urinary Bladder Neoplasms* ; Urinary Bladder*

Wilms` tumor originates from pleuripotential mesenchymal cells of the metanephrogenic blastema. Improvement on surgery and anesthesia, addition of radiation therapy and chemotherapy have produced remarkable improvements in survival over the past several decades. Twenty-eight patients with histologically confirmed diagnoses of Wilms` tumor were treated from l972 through l987 at the University Hospital, Keimyung University School of Medicine. l. Two year survival rate according to tumor stage was 80% in stage I, 7516 in stage II , 57.1% in stage III and 25% in stage IV and the overall 2 year survival rate was 57.1 1K . 2. Two year survival rate according to age was 75% in below l year, 50% between l to 2 years old, 54.5% between 2 to 6 years old and 60% above 6 years old. However, there seems to be no close relationship between age and prognosis. 3. Two year survival rate before 1978 was 45.5% and after 1978 was 45.5% and after 1978 it was 61.6% 4. There was 76.0 percent overall survival for those with negative nodes versus 33.3 per cent survival for those with positive nodes. 5. Two year survival rates of FH(Favorable Histology) and UH(Unfavorable Histology) were 68.2% and 16.7% respectively. There seems to be close relationship between FH and UH.
Anesthesia ; Child ; Child, Preschool ; Diagnosis ; Drug Therapy ; Humans ; Prognosis* ; Survival Rate

In adenomatous polyposis coli there are many colonic and extracolonic manifestations, and various combinations of these induce different clinical presentations and syndromes. We experienced a unique case of adenomatous polyposis of the large intestine and stomach in a 39-year-old man. In the colon, small cell neuroendocrine carcinoma rather than adenocarcinoma had developed, which did not contain adenomatous or carcinomatous foci. The adenomatous polyps in the colon were all small and sessile with no cancerous or precancerous change two years after the resection of the symptomatic gastric adenomas, even though the gastric adenomas were larger and showed dysplastic change. We think this case is another variant of adenomatous polyposis syndrome.
Adenocarcinoma ; Adenoma

No abstract available.
Diagnosis* ; Ultrasonography* ; Varicocele*

HPV infection has been implicated strongly in the pathogenesis of human squamous cell carcinoma(SCC). We analysed a series of 28 surgically removed, invasive squamous cell carcinoma of the esophagus by polymerase chain reaction to detect HPV DNA using consensus primers and 8 type-specific primers of HPV (6, 11, 16, 18, 31, 33, 35, 51). HPV 6, 31, 35 or 51 DNA were detected in 20 out of 28 cases (71.4%) of the esophageal SCCs. HPV 51 was the most frequently detected type, occuring in 13 out of 28 cases (46.4%). p53 immunohistochemical staining was also performed to demonstrate any relationship to HPV DNA positivity. It showed positivity in 16 out of 28(57.1%) esophageal SCCs, and HPV DNA and p53 positivity were concurrently detected in 11 out of 28 cases of SCCs. There was no significant inverse relation between HPV DNA positivity and p53 expression(p>0.05). Our results supported HPV involvement in esophageal squamous cell carcinoma, and suggested there may be another pathway not related to the p53-binding pathway in the carcinogenesis of esophageal SCCs by HPV.
Humans